Výsledky vyhledávání - "T H, LeJemtel"

[Functional mitral insufficiency: a neglected vascular lesion?]

Autor: P V, Ennezat, D, Logeart, J, Lachmann, T H, LeJemtel, A, Cohen-Solal

Publikováno v: Archives des maladies du coeur et des vaisseaux. 94(11)

Functional mitral regurgitation is usually neglected during the course of dilated cardiomyopathies. However, functional mitral regurgitation is a sensitive marker of decreased survival. Recent development of treatments such as new surgical approach,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a4b4afc562d025951d9d3fa4cda72208
https://pubmed.ncbi.nlm.nih.gov/11794985

Zobrazit plný text záznamu

Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators

Autor: P J, de Kam, A A, Voors, M P, van den Berg, D J, van Veldhuisen, J, Brouwer, H J, Crijns, C, Borghi, E, Ambrosioni, J S, Hochman, T H, LeJemtel, J H, Kingma, M S, Sutton, W H, van Gilst

Publikováno v: Journal of the American College of Cardiology. 36(7)

We sought to investigate the effect of angiotensin-converting enzyme (ACE) inhibition9 h after myocardial infarction (MI) on left ventricular (LV) dilation in patients receiving thrombolysis.The ACE inhibitors reduce mortality after MI. Attenuation o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2088c0c1a5deafc756cfe3c227959233
https://pubmed.ncbi.nlm.nih.gov/11127440

Zobrazit plný text záznamu

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

Autor: M T, Slawsky, W S, Colucci, S S, Gottlieb, B H, Greenberg, E, Haeusslein, J, Hare, S, Hutchins, C V, Leier, T H, LeJemtel, E, Loh, J, Nicklas, D, Ogilby, B N, Singh, W, Smith

Publikováno v: Circulation. 102(18)

We determined the short-term hemodynamic and clinical effects of levosimendan, a novel calcium-sensitizing agent, in patients with decompensated heart failure.One hundred forty-six patients with New York Heart Association functional class III or IV h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::771d0d56cbac09e8e4f06e40ef78d334
https://pubmed.ncbi.nlm.nih.gov/11056096

Zobrazit plný text záznamu

Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group

Autor: B D, Lowes, M, Higginbotham, L, Petrovich, M A, DeWood, M A, Greenberg, P S, Rahko, G W, Dec, T H, LeJemtel, R L, Roden, M M, Schleman, A D, Robertson, R J, Gorczynski, M R, Bristow

Publikováno v: Journal of the American College of Cardiology. 36(2)

This study was designed to evaluate the effects of low-dose enoximone on exercise capacity.At higher doses the phosphodiesterase inhibitor, enoximone, has been shown to increase exercise capacity and decrease symptoms in heart failure patients but al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e2e3f05c729f38698b654799f1f7dc6c
https://pubmed.ncbi.nlm.nih.gov/10933364

Zobrazit plný text záznamu

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock

Autor: J S, Hochman, L A, Sleeper, J G, Webb, T A, Sanborn, H D, White, J D, Talley, C E, Buller, A K, Jacobs, J N, Slater, J, Col, S M, McKinlay, T H, LeJemtel

Publikováno v: The New England journal of medicine. 341(9)

The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock.Patients with shock due to left ventricul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2062a56fac13bccbd9be103f6a58e6a0
https://pubmed.ncbi.nlm.nih.gov/10744499

Zobrazit plný text záznamu

Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group

Autor: R M, Mills, T H, LeJemtel, D P, Horton, C, Liang, R, Lang, M A, Silver, C, Lui, K, Chatterjee

Publikováno v: Journal of the American College of Cardiology. 34(1)

The goal of this study was to further define the role of nesiritide (human b-type natriuretic peptide) in the therapy of decompensated heart failure (HF) by assessing the hemodynamic effects of three doses (0.015, 0.03 and 0.06 microg/kg/min) adminis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8667ccd903cb88cd6e9e42baf7c05b3d
https://pubmed.ncbi.nlm.nih.gov/10400005

Zobrazit plný text záznamu

Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group

Autor: S D, Katz, M, Radin, T, Graves, C, Hauck, A, Block, T H, LeJemtel

Publikováno v: Journal of the American College of Cardiology. 34(1)

The purpose of this study was to determine the acute and chronic effects of cyclooxygenase inhibition with aspirin and thromboxane A2 receptor blockade with ifetroban on the chronic vasodilating effects of enalapril in the skeletal muscle circulation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::179ceeab9e3a92b1e817c948a870c202
https://pubmed.ncbi.nlm.nih.gov/10400007

Zobrazit plný text záznamu

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise

Autor: M, Packer, W S, Colucci, J D, Sackner-Bernstein, C S, Liang, D A, Goldscher, I, Freeman, M L, Kukin, V, Kinhal, J E, Udelson, M, Klapholz, S S, Gottlieb, D, Pearle, R J, Cody, J J, Gregory, N E, Kantrowitz, T H, LeJemtel, S T, Young, M A, Lukas, N H, Shusterman

Publikováno v: Circulation. 94(11)

Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials.We enrolled 278 patients with moderate to severe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::6595c49957bbffac8ea6e41d98735c28
https://pubmed.ncbi.nlm.nih.gov/9495309

Zobrazit plný text záznamu

Heart failure: its progression and its therapy

Autor: E H, Sonnenblick, T H, LeJemtel

Publikováno v: Hospital practice (Office ed.). 28(9)

The complex pathology that leads to heart failure has hampered the search for optimal therapy. Even so, ACE inhibitors have become a cornerstone of treatment. After an acute MI, the goal of ACE inhibition is to limit LV remodeling and progression to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f60cc5a45d62baa0e38829f1958b4830
https://pubmed.ncbi.nlm.nih.gov/8366150

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání